The groundbreaking rise of Viagra has firmly established as a benchmark of pharmaceutical success, yet its legacy within the broader market now presents questions about long-term yields . Generic versions are diminishing market share, causing concerns that investing in companies heavily reliant to Viagra's once-dominant position could be a problema